MCL1特异性抑制剂S63845与维奈托克/ABT-199协同作用，诱导T细胞急性淋巴细胞白血病细胞凋亡。 - Suppr

Suppr

超能文献

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.

作者信息

Li Zhaodong, He Shuning, Look A Thomas

机构信息

Department of Paediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.

Division of Haematology/Oncology, Boston Children's Hospital, Boston, MA, 02215, USA.

出版信息

Leukemia. 2019 Jan;33(1):262-266. doi: 10.1038/s41375-018-0201-2. Epub 2018 Jul 15.

DOI:10.1038/s41375-018-0201-2

PMID:30008477

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6327051/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fbc/6327051/4b5b832b045f/41375_2018_201_Fig1_HTML.jpg

相似文献

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.MCL1特异性抑制剂S63845与维奈托克/ABT-199协同作用，诱导T细胞急性淋巴细胞白血病细胞凋亡。

Leukemia. 2019 Jan;33(1):262-266. doi: 10.1038/s41375-018-0201-2. Epub 2018 Jul 15.

Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.联合 MCL-1 抑制与 venetoclax 可提高 AML 中 BH3 模拟物的治疗效果。

Eur J Haematol. 2020 Nov;105(5):588-596. doi: 10.1111/ejh.13492. Epub 2020 Aug 4.

Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.维奈托克、硼替佐米和S63845（一种MCL1抑制剂）用于治疗多发性骨髓瘤。

J Pharm Pharmacol. 2020 May;72(5):728-737. doi: 10.1111/jphp.13240. Epub 2020 Feb 17.

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss.在由NF1/PTEN缺失驱动的高危肿瘤中，通过抑制MCL1和BCL2介导的协同性黑色素瘤细胞死亡。

Oncogene. 2021 Sep;40(38):5718-5729. doi: 10.1038/s41388-021-01926-y. Epub 2021 Jul 30.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal in Relapsed Mantle Cell Lymphoma.维奈托克联合 S63845 靶向 BCL2 和 MCL1 对复发性套细胞淋巴瘤具有合成致死作用。

Clin Cancer Res. 2019 Jul 15;25(14):4455-4465. doi: 10.1158/1078-0432.CCR-18-3275. Epub 2019 Apr 19.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.针对费城染色体阳性急性淋巴细胞白血病中的 BCL-2 和 ABL/LYN。

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.肿瘤靶向纳米颗粒提高了 BCL2 和 MCL1 双重抑制的治疗指数。

Blood. 2021 Apr 15;137(15):2057-2069. doi: 10.1182/blood.2020008017.

Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.维奈托克与基于天冬酰胺酶的化疗联合用于复发/难治性成人急性淋巴细胞白血病患者的可行性

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e441-e444. doi: 10.1016/j.clml.2018.07.289. Epub 2018 Aug 27.

Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.细胞周期蛋白依赖性激酶（CDK）抑制剂LS-007作为单一药物以及与ABT-199联合使用对人急性白血病细胞的抗肿瘤作用。

Acta Pharmacol Sin. 2016 Nov;37(11):1481-1489. doi: 10.1038/aps.2016.49. Epub 2016 Aug 29.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.通过共同靶向 MCL1 增强急性髓系白血病中的 venetoclax 活性。

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

引用本文的文献

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies.超氧化物介导的AKT对Mcl-1的磷酸化和稳定作用是血液系统恶性肿瘤中维奈克拉耐药的基础。

Leukemia. 2025 Jul 24. doi: 10.1038/s41375-025-02694-4.

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non-Canonical Amino Acids for Coinhibition of MCL-1 and BCL-xL in Acute Myeloid Leukemia.BH3模拟物的靶向穿透基序工程：利用非天然氨基酸协同抑制急性髓系白血病中的MCL-1和BCL-xL

Adv Sci (Weinh). 2025 Jul;12(27):e2503682. doi: 10.1002/advs.202503682. Epub 2025 Apr 30.

Promising Drugs Targeting Specific Mechanisms of Deregulation in T Cell Lineage Acute Lymphoblastic Leukemia.针对T细胞系急性淋巴细胞白血病特定失调机制的有前景的药物

Oncol Ther. 2025 Apr 18. doi: 10.1007/s40487-025-00339-1.

Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.Notch抑制剂与BH3模拟物在T细胞急性淋巴细胞白血病中的应用

Int J Mol Sci. 2024 Nov 29;25(23):12839. doi: 10.3390/ijms252312839.

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis.KS18是一种Mcl-1抑制剂，它通过触发内源性凋亡来提高硼替佐米的有效性，并克服难治性多发性骨髓瘤的耐药性。

Front Pharmacol. 2024 Oct 1;15:1436786. doi: 10.3389/fphar.2024.1436786. eCollection 2024.

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.MCL-1 抑制剂 AZD5991 在复发/难治性血液系统恶性肿瘤患者中的 1 期首次人体研究。

Clin Cancer Res. 2024 Nov 1;30(21):4844-4855. doi: 10.1158/1078-0432.CCR-24-0028.

Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells.二甲双胍作为一种增强剂治疗耐药性 CD34+急性髓系白血病细胞。

Genes (Basel). 2024 May 20;15(5):648. doi: 10.3390/genes15050648.

Venetoclax Drug Increases the Apoptosis of T and B Acute Lymphoblastic Leukemia Cells by Reducing the Expression of .维奈托克药物通过降低……的表达增加T和B急性淋巴细胞白血病细胞的凋亡。

Int J Mol Cell Med. 2023;12(3):229-241. doi: 10.22088/IJMCM.BUMS.12.3.229.

Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.靶向 hMcl-1 的组氨酸共价键合的螺旋肽

J Med Chem. 2024 May 23;67(10):8172-8185. doi: 10.1021/acs.jmedchem.4c00277. Epub 2024 May 2.

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x/Bcl-w Inhibitors.联合 Mcl-1 和 Bcl-2/Bcl-x/Bcl-w 抑制剂靶向黑色素瘤细胞。

Int J Mol Sci. 2024 Mar 19;25(6):3453. doi: 10.3390/ijms25063453.

本文引用的文献

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.在三阴性和 HER2 扩增型乳腺癌的临床前模型中，MCL-1 抑制剂 S63845 与现有疗法的协同作用。

Sci Transl Med. 2017 Aug 2;9(401). doi: 10.1126/scitranslmed.aam7049.

To Prime, or Not to Prime: That Is the Question.启动，还是不启动：这是个问题。

Cold Spring Harb Symp Quant Biol. 2016;81:131-140. doi: 10.1101/sqb.2016.81.030841. Epub 2016 Nov 3.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.MCL1 抑制剂 S63845 在多种癌症模型中具有良好的耐受性和疗效。

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.BCR 信号抑制剂在克服 CLL B 细胞对 ABT-199 的 Mcl-1 介导的耐药性方面存在差异。

Blood. 2016 Jun 23;127(25):3192-201. doi: 10.1182/blood-2015-10-675009. Epub 2016 Apr 19.

Mitochondria-Judges and Executioners of Cell Death Sentences.线粒体——细胞死亡判决的评判者与执行者

Mol Cell. 2016 Mar 3;61(5):695-704. doi: 10.1016/j.molcel.2016.02.019.

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.BCL-2 三十年：将细胞死亡发现转化为新型癌症疗法。

Nat Rev Cancer. 2016 Feb;16(2):99-109. doi: 10.1038/nrc.2015.17.

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.在淋巴系统恶性肿瘤中，通过阻止PI3K/AKT/mTOR激活，可以克服对BCL-2抑制剂ABT-199的MCL-1和BCL-xL依赖性耐药。

Cell Death Dis. 2015 Jan 15;6(1):e1593. doi: 10.1038/cddis.2014.525.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).强效且具选择性的小分子MCL-1抑制剂作为单一药物以及与ABT-263（维托克洛克斯）联合使用时，均表现出靶向癌细胞杀伤活性。

Cell Death Dis. 2015 Jan 15;6(1):e1590. doi: 10.1038/cddis.2014.561.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.ABT-199 通过抑制 BCL-2 作为 T 细胞急性淋巴细胞白血病的一种新的治疗策略。

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.T细胞急性淋巴细胞白血病的成熟阶段决定了对BCL-2与BCL-XL的依赖性以及对ABT-199的敏感性。

Cancer Discov. 2014 Sep;4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353. Epub 2014 Jul 3.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验